NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00798369
- Locations
- 🇺🇸
Montana Medical Research, Missoula, Montana, United States
🇺🇸Northwest Clinical Trials, Boise, Idaho, United States
🇬🇧Novartis Investigative Site, Wellingborough, United Kingdom
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 532
- Registration Number
- NCT00797316
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1254
- Registration Number
- NCT00797862
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 31
- Registration Number
- NCT00795418
- Locations
- 🇺🇸
NOCCR Knoxville, Knoxville, Tennessee, United States
🇺🇸ATP Clinical Research, Costa Mesa, California, United States
🇺🇸Alpine Clinical Research Center, Boulder, Colorado, United States
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 860
- Registration Number
- NCT00787605
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT00785083
- Locations
- 🇬🇧
Novartis Investigator Site, Manchester, United Kingdom
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
- Conditions
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 44
- Registration Number
- NCT00784732
- Locations
- 🇨🇦
Novartis Investigator Site, Toronto, Canada
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 847
- Registration Number
- NCT00778921
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 818
- Registration Number
- NCT00777946
- Locations
- 🇻🇪
Investigative Site, Venezuela, Venezuela
🇮🇹Investigative site, Italy, Italy
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 386
- Registration Number
- NCT00772577
- Locations
- 🇺🇸
Investigative Site, Houston, Texas, United States